We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of LY3361237 in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03695198
Recruitment Status : Completed
First Posted : October 4, 2018
Last Update Posted : September 4, 2019
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:

The purposes of this study are to determine:

  • The safety of LY3361237 and any side effects that might be associated with it.
  • How much LY3361237 gets into the blood stream and how long it takes the body to remove it in healthy participants.

Participants will be admitted to the clinical research unit (CRU) for 4 overnight stays. The study will last about 12 weeks for each participant, not including screening.

Condition or disease Intervention/treatment Phase
Healthy Drug: LY3361237 - SC Drug: LY3361237 - IV Drug: Placebo - SC Drug: Placebo - IV Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3361237 in Healthy Subjects
Actual Study Start Date : October 26, 2018
Actual Primary Completion Date : August 29, 2019
Actual Study Completion Date : August 29, 2019

Arm Intervention/treatment
Experimental: LY3361237 - Subcutaneous (SC)
LY3361237 administered SC
Drug: LY3361237 - SC
LY3361237 administered SC

Placebo Comparator: Placebo - SC
Placebo administered SC
Drug: Placebo - SC
Placebo administered SC

Experimental: LY3361237 - Intravenous (IV)
LY3361237 administered IV
Drug: LY3361237 - IV
LY3361237 administered IV

Placebo Comparator: Placebo - IV
Placebo administered IV
Drug: Placebo - IV
Placebo administered IV

Primary Outcome Measures :
  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through Week 12 ]
    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Secondary Outcome Measures :
  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3361237 [ Time Frame: Predose through Week 12 ]
    PK: Cmax of LY3361237

  2. PK: Area Under the Plasma Concentration Time Curve (AUC) of LY3361237 [ Time Frame: Predose through Week 12 ]
    PK: AUC of LY3361237

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy males or females, as determined by medical history and physical examination.
  • To qualify as Japanese for this study, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.
  • Between 18 (20 for Japanese participants) and 65 years of age.
  • Have a body mass index of 18.0 to 32.0 kilograms per meter squared, inclusive, and a minimum body weight of 45.0 kilograms.

Exclusion Criteria:

  • Show evidence of active or latent tuberculosis (TB), as documented by medical history and examination, chest x-ray and TB testing
  • Are immunocompromised
  • Have evidence of chronic viral infection have received live vaccine(s) (including attenuated live vaccines) within 28 days of screening or intend to receive during the study (non-live or inactivated vaccinations are allowed). Bacillus Calmette-Guérin (BCG) vaccine must not have been administered within 12 months of screening
  • Have had lymphoma, leukemia, or any malignancy or pre-malignant condition within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03695198

Layout table for location information
United States, California
California Clinical Trials Medical Group
Glendale, California, United States, 91206
Sponsors and Collaborators
Eli Lilly and Company
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT03695198    
Other Study ID Numbers: 16969
I9S-MC-BTAA ( Other Identifier: Eli Lilly and Company )
First Posted: October 4, 2018    Key Record Dates
Last Update Posted: September 4, 2019
Last Verified: September 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No